Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 9
Submit an article Journal homepage
167
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation

Julian Lindsaya National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia;b Haematology Department, Royal North Shore Hospital, Sydney, Australia;c Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7086-538XView further author information
ORCID Icon,
Matthew Greenwoodb Haematology Department, Royal North Shore Hospital, Sydney, Australia;d Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, AustraliaView further author information
,
Jad Othmanb Haematology Department, Royal North Shore Hospital, Sydney, AustraliaView further author information
,
Sharon C.-A. Chene Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, The University of Sydney, and the Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney, AustraliaView further author information
,
David C. M. Kongf NHMRC National Centre for Antimicrobial Stewardship at The Peter Doherty Institute for Infections and Immunity, Parkville, Victoria, Australia;g Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia;h Pharmacy Department, Ballarat Health Services, Ballarat, Victoria, AustraliaORCID Iconhttps://orcid.org/0000-0002-5022-9060View further author information
ORCID Icon,
Steven A. Pergamc Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;i Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, USAORCID Iconhttps://orcid.org/0000-0002-6333-5196View further author information
ORCID Icon,
Catherine Liuc Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;i Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, USAView further author information
&
Monica A. Slavina National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia;j Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;k Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaORCID Iconhttps://orcid.org/0000-0002-8443-314XView further author information
ORCID Icon show all
Pages 2254-2256 | Received 11 Feb 2022, Accepted 01 Apr 2022, Published online: 15 Apr 2022
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

JL has served on advisory boards for Mayne Pharma, MSD, Amgen, Gilead and BMS, unrelated to this current work. DCMK has served on advisory boards for Becton Dickinson Pty Ltd and Merck Sharp & Dohme (MSD), and received financial support from MSD and F2G, unrelated to the current work. SAP receives research support from Global Life Technologies, Inc., and participated in research trials with Chimerix, Inc and Merck & Co unrelated to this current work. He participated in a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (U01-AI132004). MG has served on advisory boards for Amgen, Pfizer, MSD, Servier and Jazz Pharmaceuticals and has received clinical trial and research support from Amgen and Servier unrelated to this current work. MAS, JO, SC-AC, and CL have no relevant COIs. No potential conflict of interest was reported by the author(s).

Additional information

Funding

JL is supported by a Leukaemia Foundation (LF) and Haematology Society of Australia and New Zealand (HSANZ) New Investigator PhD Scholarship. MAS is supported by NHMRC CRE and Investigator Grants [1116876 and 1173791].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.